keyword
MENU ▼
Read by QxMD icon Read
search

Fecal calprotectin

keyword
https://www.readbyqxmd.com/read/28447072/a-randomized-trial-of-the-effects-of-the-no-carrageenan-diet-on-ulcerative-colitis-disease-activity
#1
Sumit Bhattacharyya, Theresa Shumard, Hui Xie, Amar Dodda, Krista A Varady, Leo Feferman, Allan G Halline, Jay L Goldstein, Stephen B Hanauer, Joanne K Tobacman
BACKGROUND: Carrageenan is a very common food additive in Western diets, but predictably causes inflammation in thousands of cell-based and animal experiments. OBJECTIVE: To assess the impact of carrageenan exposure on the interval to relapse in patients with ulcerative colitis in remission. METHODS: A randomized, double-blind, placebo-controlled, multicenter, clinical trial was conducted to assess if patients with ulcerative colitis in remission would have a longer interval to relapse if they followed a diet with no carrageenan...
March 31, 2017: Nutrition and Healthy Aging
https://www.readbyqxmd.com/read/28442839/the-place-of-calprotectin-lactoferrin-and-high-mobility-group-box-1-protein-on-diagnosis-of-acute-appendicitis-with-children
#2
Sevgi Buyukbese Sarsu, Ayse Binnur Erbagci, Hasan Ulusal, Suleyman Cuneyt Karakus, Özlem Gümüstekin Bulbul
The purpose of this study is to investigate the role of serum calprotectin (CP), lactoferrin (LF), and high-mobility group protein B1 (HMGB-1) levels and fecal CP and LF levels in differential diagnosis of acute uncomplicated appendicitis from other causes of abdominal pain and further from complicated appendicitis. Totally, 120 children were included grouped into 4 as: healthy controls, patients with right lower quadrant pain with other than surgical causes, patients with uncomplicated appendicitis, and patients with complicated appendicitis...
April 2017: Indian Journal of Surgery
https://www.readbyqxmd.com/read/28442699/does-the-rapid-fecal-calprotectin-test-equally-predict-mucosal-inflammation-in-both-ulcerative-colitis-uc-and-crohn-s-disease-cd-a-prospective-analysis-of-an-ibd-cohort
#3
Andrzej Moniuszko, Stanisław Głuszek, Grażyna Rydzewska
INTRODUCTION    Fecal calprotectin (FC) is a well-established biomarker of intestinal inflammation in CD and UC. However, standard laboratory methods are time consuming and not always useful in clinical practice.  OBJECTIVES    We analyzed the efficacy of a rapid bedside FC test to detect disease flares in a hospital setting. We also assessed the influence of disease location on diagnostic accuracy. PATIENTS AND METHODS    140 patients were prospectively enrolled in the study (46 UC, 94 CD). FC was measured both by ELISA and by the rapid Quantum Blue® test...
April 26, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28426458/anti-tnf%C3%AE-treatment-after-surgical-resection-for-crohn-s-disease-is-effective-despite-previous-pharmacodynamic-failure
#4
Amit Assa, Jiri Bronsky, Kaija-Leena Kolho, Kristyna Zarubova, Tim de Meij, Oren Ledder, Margaret Sladek, Stephanie van Biervliet, Caterina Strisciuglio, Raanan Shamir
BACKGROUND: The outcome of patients with Crohn's disease who failed anti-tumor necrosis factor alpha (anti-TNFα) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNFα agent postoperatively. METHODS: Pediatric patients with Crohn's disease who underwent intestinal resection and were treated with anti-TNFα agents postoperatively were assessed retrospectively...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28423962/the-utility-of-fecal-calprotectin-in-predicting-the-need-for-escalation-of-therapy-in-inflammatory-bowel-disease
#5
Lukasz Kwapisz, Jamie Gregor, Nilesh Chande, Brian Yan, Terry Ponich, Mahmoud Mosli
BACKGROUND AND AIMS: Fecal calprotectin is an important biomarker used in the evaluation of inflammatory bowel disease. It has proven to be an effective tool in initial screening as well monitoring response to therapy. The aim of this study is to examine the utility of fecal calprotectin both as a predictor for the escalation of therapy in established inflammatory bowel disease and as a predictor of de novo diagnosis. METHODS: Patients with signs and symptoms concerning for inflammatory bowel disease presenting to outpatient clinics were recruited to provide fecal calprotectin stool samples prior to endoscopic evaluation...
April 20, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28421251/defining-the-ultrasound-longitudinal-natural-history-of-newly-diagnosed-pediatric-small-bowel-crohn-disease-treated-with-infliximab-and-infliximab-azathioprine-combination-therapy
#6
Jonathan R Dillman, Soudabeh Fazeli Dehkordy, Ethan A Smith, Michael A DiPietro, Ramon Sanchez, Vera DeMatos-Maillard, Jeremy Adler, Bin Zhang, Andrew T Trout
BACKGROUND: Little is known about changes in the imaging appearances of the bowel and mesentery over time in either pediatric or adult patients with newly diagnosed small bowel Crohn disease treated with anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. OBJECTIVE: To define how bowel ultrasound findings change over time and correlate with laboratory inflammatory markers in children who have been newly diagnosed with pediatric small bowel Crohn disease and treated with infliximab...
April 18, 2017: Pediatric Radiology
https://www.readbyqxmd.com/read/28420947/the-use-of-fecal-calprotectin-in-inflammatory-bowel-disease
#7
Ingvar Bjarnason
No abstract text is available yet for this article.
January 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28416415/age-dependent-variation-of-fecal-calprotectin-in-cystic-fibrosis-and-healthy-children
#8
Millie Garg, Steven T Leach, Michael J Coffey, Tamarah Katz, Roxanne Strachan, Tamara Pang, Bronwen Needham, Kei Lui, Fathalla Ali, Andrew S Day, Laura Appleton, Vesal Moeeni, Adam Jaffe, Chee Y Ooi
BACKGROUND: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). METHOD: Stools from CF patients and healthy controls (HC) (0-10years old) were prospectively collected for evaluation of temporal trends. RESULTS: 130 CF samples (64 subjects) and 114 HC samples (101 subjects) were collected. Overall, fecal calprotectin levels were different in CF patients and HC from 0 to 10years (P=0...
April 14, 2017: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://www.readbyqxmd.com/read/28410341/effects-of-transient-and-persistent-anti-drug-antibodies-to-certolizumab-pegol-longitudinal-data-from-a-7-year-study-in-crohn-s-disease
#9
William J Sandborn, Douglas C Wolf, Gordana Kosutic, Gerry Parker, Stefan Schreiber, Scott D Lee, Bincy Abraham, Anita Afzali, Razvan I Arsenescu, Alexandra Gutierrez, Marshall Spearman, Jason Coarse, Brian G Feagan
BACKGROUND: Anti-drug antibodies (ADAbs) may decrease the efficacy of biologics and increase the risk of adverse events. A single positive test may not preclude further treatment because of variations in assays used, test timing, and patient variables. We evaluated the longitudinal patterns of immunogenicity during 7 years of antitumor necrosis factor-alpha drug certolizumab pegol (CZP) treatment for moderate-to-severe Crohn's disease. METHODS: PRECiSE 3 patients (n = 595) received open-label CZP 400 mg every 4 weeks up to 7 years...
April 13, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28391117/delivery-and-feeding-mode-affects-fecal-calprotectin-levels-in-infants-7months-old
#10
Yoo Mi Lee, Chae-Yeon Min, You Jin Choi, Su Jin Jeong
BACKGROUND: Elevated fecal calprotectin (FC) is a non-invasive marker of inflammation indicating bowel disease. However, healthy infants have displayed high FC levels, with large variation. We sought to determine what factors might affect FC levels in children <6months old. METHODS: We recruited 133 healthy infants aged 0-6months from four Korean day care centers. Stool samples were analyzed by immunosorbent assay. All infants completed a questionnaire related to clinical characteristics including birth and feeding history...
April 6, 2017: Early Human Development
https://www.readbyqxmd.com/read/28365485/association-between-ustekinumab-trough-concentrations-and-clinical-biomarker-and-endoscopic-outcomes-in-patients-with-crohn-s-disease
#11
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif
BACKGROUND & AIMS: Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of tumor necrosis factor (TNF) antagonists and presence of anti-drug antibodies are associated with important clinical and endoscopic outcomes. We investigated associations between trough concentrations of ustekinumab and clinical, biomarker, and endoscopic outcomes of real-world patients with CD. METHODS: We recruited 62 patients with CD who were either refractory or intolerant to TNF antagonists, treated with ustekinumab from April 2014 to September 2015...
March 29, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28346274/the-effect-of-disease-activity-on-birth-outcomes-in-a-nationwide-cohort-of-women-with-moderate-to-severe-inflammatory-bowel-disease
#12
Heidi Kammerlander, Jan Nielsen, Jens Kjeldsen, Torben Knudsen, Sonia Friedman, Bente Nørgård
BACKGROUND: Active inflammatory bowel disease (IBD) during conception and pregnancy may increase the risk of adverse birth outcomes. Former studies have examined heterogeneous groups of women with varying degrees of IBD severity. We aimed to examine the effect of active IBD on birth outcomes in a more homogeneous group of women with a moderate to severe disease course. Since in Denmark, moderate to severe IBD is an indication for use of anti-tumor necrosis factor-α therapy, we examined all women who used anti-tumor necrosis factor therapy during pregnancy...
March 24, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28336498/pregnancy-does-not-affect-fecal-calprotectin-concentration-in-healthy-women
#13
Anita Bálint, Anna Berényi, Klaudia Farkas, Éva Pallagi Kunstár, Ábel Altorjay, Andrea Csonka, Mária Krizsán, Mónika Szűcs, Attila Pál, Anna Fábián, Renáta Bor, Ágnes Milassin, Ádám Szulcsán, Rutka Mariann, Zoltán Szepes, Tamás Molnár
BACKGROUND/AIMS: Noninvasive activity markers are extremely important in conditions, such as pregnancy, when endoscopy is not recommended. The aim of this prospective study was to determine fecal calprotectin (FC) concentrations in healthy non-pregnant and pregnant women and in patients with inflammatory bowel disease (IBD). MATERIALS AND METHODS: Healthy pregnant and non-pregnant women and patients with active and inactive IBD were prospectively enrolled in this study...
March 23, 2017: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/28328621/ocular-involvement-in-children-with-inflammatory-bowel-disease
#14
Samuele Naviglio, Fulvio Parentin, Silvia Nider, Nicolò Rassu, Stefano Martelossi, Alessandro Ventura
BACKGROUND: Data on ocular manifestations of inflammatory bowel disease (IBD) in children are limited. Some authors have reported a high prevalence of asymptomatic uveitis, yet the significance of these observations is unknown and there are no recommendations on which ophthalmologic follow-up should be offered. METHODS: Children with IBD seen at a single referral center for pediatric gastroenterology were offered ophthalmologic evaluation as part of routine care for their disease...
March 21, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28323866/elevated-fecal-peptidase-d-at-onset-of-colitis-in-galphai2-mice-a-mouse-model-of-ibd
#15
Daniel Bergemalm, Robert Kruse, Maria Sapnara, Jonas Halfvarson, Elisabeth Hultgren Hörnquist
BACKGROUND: The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms. METHODS: Fecal samples were collected at onset of inflammation in Galphai2-/- mice, a well-described spontaneous model of chronic colitis, and from healthy littermates...
2017: PloS One
https://www.readbyqxmd.com/read/28319300/mouthing-of-soil-contaminated-objects-is-associated-with-environmental-enteropathy-in-young-children
#16
Tomohiko Morita, Jamie Perin, Lauren Oldja, Shwapon Biswas, R Bradley Sack, Shahnawaz Ahmed, Rashidul Haque, Nurul Amin Bhuiyan, Tahmina Parvin, Sazzadul Islam Bhuyian, Mahmuda Akter, Kaisar A Talukder, Mohammad Shahnaij, Abu G Faruque, Christine Marie George
OBJECTIVE: To characterise childhood mouthing behaviours and to investigate the association between object-to-mouth and food-to-mouth contacts, diarrhoea prevalence and environmental enteropathy. METHODS: A prospective cohort study was conducted of 216 children ≤30 months of age in rural Bangladesh. Mouthing contacts with soil and food and objects with visible soil were assessed by 5-h structured observation. Stool was analysed for four faecal markers of intestinal inflammation: alpha-1-antitrypsin, myeloperoxidase, neopterin and calprotectin...
March 20, 2017: Tropical Medicine & International Health: TM & IH
https://www.readbyqxmd.com/read/28293713/fecal-but-not-serum-calprotectin-is-a-potential-marker-of-gvhd-after-stem-cell-transplantation
#17
Elisabetta Metafuni, Sabrina Giammarco, Daniela Giovanna De Ritis, Monica Rossi, Teresa De Michele, Cecilia Zuppi, Andrea P Bacigalupo, Simona Sica, Patrizia Chiusolo
Gastrointestinal graft-versus-host disease (GvHD) represents a life-threatening complication after stem cell transplantation. Differential diagnosis between gut GvHD and other causes of diarrhea after HSCT is still subjected to endoscopy and histological findings. The research for a reliable biomarker for gut GvHD might allow an early diagnosis of this condition and a consequent prompt treatment that could reduce unfavorable outcomes. Recently, fecal calprotectin was reported as reliable marker of gut involvement...
March 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28271623/a-double-blind-placebo-controlled-study-to-assess-the-effect-of-a-probiotic-mixture-on-symptoms-and-inflammatory-markers-in-women-with-diarrhea-predominant-ibs
#18
K Hod, A D Sperber, Y Ron, M Boaz, R Dickman, S Berliner, Z Halpern, N Maharshak, R Dekel
BACKGROUND: Micro-inflammation is considered an element in the pathogenesis of irritable bowel syndrome (IBS). High-sensitivity C reactive protein (hs-CRP) was previously shown to be higher in IBS compared to healthy controls, albeit within the normal range. Since probiotics may suppress micro-inflammation in the gut, we tested if they reduce symptoms and inflammatory markers (hs-CRP and fecal calprotectin (FC) in diarrhea-predominant IBS (IBS-D). The aim of this study was to assess the clinical and laboratory effects of BIO-25, a multispecies probiotic, in women with IBS-D...
March 8, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28248735/self-managed-ehealth-disease-monitoring-in-children-and-adolescents-with-inflammatory-bowel-disease-a-randomized-controlled-trial
#19
Katrine Carlsen, Christian Jakobsen, Gunnar Houen, Thomas Kallemose, Anders Paerregaard, Lene B Riis, Pia Munkholm, Vibeke Wewer
BACKGROUND: To evaluate the impact of eHealth on disease activity, the need for hospital contacts, and medical adherence in children and adolescents with inflammatory bowel disease (IBD). Furthermore, to assess eHealth's influence on school attendance and quality of life (QoL). METHODS: Patients with IBD, 10 to 17 years attending a public university hospital, were prospectively randomized to a 2-year open label case-controlled eHealth intervention. The eHealth-group used the web-application young...
February 13, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28244677/using-ehealth-strategies-in-delivering-dietary-and-other-therapies-in-patients-with-irritable-bowel-syndrome-and-inflammatory-bowel-disease
#20
REVIEW
Dorit Vedel Ankersen, Katrine Carlsen, Dorte Marker, Pia Munkholm, Johan Burisch
Health-care systems around the world are facing increasing costs. Non-adherent, chronically ill patients are one such expense incurred by health-care providers. Web-based home-monitoring of patients-or eHealth-has been shown to increase adherence to medical therapy, facilitate contact between patients and health-care professionals, and reduce time to remission for patients with inflammatory bowel disease (IBD). Web-based treatment is a supportive tool for the health-care provider in an out-patient clinic. eHealth web-programs, such as the Constant Care application, visualize disease activity in a traffic light system and empower patients to screen for disease activity, enabling them to respond appropriately to their symptoms...
March 2017: Journal of Gastroenterology and Hepatology
keyword
keyword
27773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"